Fas ligand deficiency impairs tumor immunity by promoting an accumulation of monocytic myeloid-derived suppressor cells

S Peyvandi, S Buart, B Samah, M Vétizou, Y Zhang… - Cancer Research, 2015 - AACR
S Peyvandi, S Buart, B Samah, M Vétizou, Y Zhang, L Durrieu, M Polrot, S Chouaib
Cancer Research, 2015AACR
Abstract The Fas receptor ligand FasL regulates immune cell levels by inducing apoptosis of
Fas receptor–positive cells. Here, we studied the impact of host FasL on tumor development
in mice. Genetically targeting FasL in naïve mice increased myeloid cell populations, but, in
marked contrast, it reduced the levels of myeloid-derived suppressor cells (MDSC) in mice
bearing Lewis lung carcinoma tumors. Analysis of the MDSC subset distribution revealed
that FasL deficiency skewed cell populations toward the M-MDSC subset, which displays a …
Abstract
The Fas receptor ligand FasL regulates immune cell levels by inducing apoptosis of Fas receptor–positive cells. Here, we studied the impact of host FasL on tumor development in mice. Genetically targeting FasL in naïve mice increased myeloid cell populations, but, in marked contrast, it reduced the levels of myeloid-derived suppressor cells (MDSC) in mice bearing Lewis lung carcinoma tumors. Analysis of the MDSC subset distribution revealed that FasL deficiency skewed cell populations toward the M-MDSC subset, which displays a highly immunosuppressive activity. Furthermore, tumor-bearing mice that were FasL-deficient displayed an enhanced proportion of tumor-associated macrophages and regulatory T cells. Overall, the immunosuppressive environment produced by FasL targeting correlated with reduced survival of tumor-bearing mice. These results disclose a new role for FasL in modulating immunosuppressive cells. Cancer Res; 75(20); 4292–301. ©2015 AACR.
AACR